Allarity Therapeutics, Inc.
No SEC Form 4 filings for $ALLR in the last 30 days.
See all $ALLR insider activity →Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030215701ex99-1.htm PRESS RELEASE, DATED JUNE 30, 2026 Exhibit 99.1 Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - Completed quarter with $26.9 million in cash and restricted cash - Key
Allarity Therapeutics (NASDAQ: ALLR) reported Q2 2026 results and said it ended June 30 with $26.9 million in cash and restricted cash. The company said the USPTO granted a key patent for its stenoparib-specific DRP companion diagnostic through April 2042, and it completed its stenoparib Phase 3-ready manufacturing campaign and obtained CLIA certification for in-house DRP testing.
Allarity Therapeutics (NASDAQ: ALLR) said it obtained CLIA Certificate of Registration for its in-house laboratory in Horsholm, Denmark, enabling it to run DRP® biomarker testing internally for FDA registration-related studies. The company expects faster turnaround, streamlined trial communication, and lower long-term costs, and may offer CLIA-compliant testing services to partners.
Over the past 7 days, alphai's AI scored 2 news stories mentioning ALLR (Allarity Therapeutics, Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent ALLR coverage spans financial news, earnings and regulation.
Patent grant and completed API manufacturing campaign reduce key execution and IP risks ahead of a registrational Phase 3 step.
Patent exclusivity plus completed Phase 3-ready manufacturing and CLIA in-house DRP testing reduce execution risk ahead of a registrational Phase 3 trial.
CLIA certification reduces execution friction for DRP companion diagnostic testing, potentially accelerating stenoparib’s FDA-bound development timeline.
The 8-K is a corporate governance update plus a fresh IP/regulatory milestone (USPTO patent grant) that can support valuation for the DRP diagnostic program.
The issuance of 133,333 RSUs at no share price suggests insider confidence and potential future stock appreciation, contingent on company performance.
alphai scores every news story that mentions ALLR with an AI model for sentiment and relevance, and aggregates insider trades from Allarity Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Allarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030215701ex99-1.htm PRESS RELEASE, DATED JUNE 30, 2026 Exhibit 99.1 Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - Completed quarter with $26.9 million in cash and restricted cash - Key
6 min readAllarity Therapeutics (NASDAQ: ALLR) reported Q2 2026 results and said it ended June 30 with $26.9 million in cash and restricted cash. The company said the USPTO granted a key patent for its stenoparib-specific DRP companion diagnostic through April 2042, and it completed its stenoparib Phase 3-ready manufacturing campaign and obtained CLIA certification for in-house DRP testing.
6 min readAllarity Therapeutics (NASDAQ: ALLR) said it obtained CLIA Certificate of Registration for its in-house laboratory in Horsholm, Denmark, enabling it to run DRP® biomarker testing internally for FDA registration-related studies. The company expects faster turnaround, streamlined trial communication, and lower long-term costs, and may offer CLIA-compliant testing services to partners.
4 min readAllarity Therapeutics, Inc. (ALLR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001860657 0001860657 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Repor
4 min readAllarity Therapeutics (ALLR) officer Jeremy R. Graff was granted 133,333 Restricted Stock Units (RSUs) on January 28, 2026, as equity compensation. These RSUs, awarded at $0.00 per share, will vest in three equal annual installments, contingent on Graff's continued employment. Following this transaction, Graff directly holds 381,644 shares of the company's common stock.
2 min readAllarity Therapeutics, Inc. has filed a preliminary proxy statement (Form PRE 14A) for its 2026 Annual Meeting of Stockholders, scheduled for June 26, 2026. Shareholders will vote on director election, auditor ratification, increasing the 2021 Equity Incentive Plan reserve by 500,000 shares, a non-binding say-on-pay proposal, approval for shares issued under an equity line impacting the Nasdaq 20% Rule, and an amendment to permit officer exculpation which requires a 66-2/3% vote. The document also details the company's executive and director compensation, risk oversight, and related party transactions.
3 min readAllarity Therapeutics recently secured an additional $250,000 in a private placement, following an initial $2.5 million raised in September 2025, to fund general corporate purposes and working capital. Despite this financing, Spark, TipRanks' AI Analyst, rates ALLR as "Underperform" due to significant financial challenges and a bearish technical trend. The company, focused on cancer therapies, has a current market capitalization of $16.28 million.
2 min read• Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trial
3 min read- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily ...
2 min readTARPON SPRINGS, Fla., September 17, 2025 - Allarity Therapeutics, Inc. ( "Allarity" or the "Company" ) ( NASDAQ: ALLR ) , a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated, dual PARP and WNT pathway inhibitor-today announced that its CEO, Thomas ...
3 min read
